XALKORI CASE STUDY
In both phase III studies, most adverse events were of grade 1 or 2 severity [ 26 , 27 ]. A previous study proved that HGF stimulates epithelial cell proliferation, motility, morphogenesis, and angiogenesis via tyrosine phosphorylation of its receptor, c-Met, and plays a role in self-repair of various injured organs [ 8 ]. With regard to the adverse effects, crizotinib was demonstrated to be tolerable 3 , 4. Open in a separate window. Additionally, the same study listed several adverse events which could be associated with the esophagus, such as heartburn and reflux esophagitis 8.
This article has been cited by other articles in PMC. In both phase III studies, most adverse events were of grade 1 or 2 severity [ 26 , 27 ]. Before beginning crizotinib, patients should be warned that visual disturbances may occur and that they might affect activities such as driving in the dark [ 34 ]. Electrocardiographic monitoring should be considered for patients with a history of cardiac disease and in those taking medications associated with QTc prolongation. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. NSCLC is a common cancer and has a very poor prognosis. Nat Rev Clin Oncol.
However, the patient relapsed with bone metastasis of the 10th thoracic vertebra and elevation of serum carcinoembryonic antigen CEA levels from 3. During these multiple chemotherapy regimens, she developed neutropenia of no higher than grade 2 in severity according to the Common Toxicity Criteria for Adverse Events ver.
Activity and sstudy of crizotinib in xalkoir with ALK-positive non-small-cell lung cancer: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Disclosure Statement All authors have no potential conflicts of interest.
These patients were enrolled into an expanded cohort of an ongoing phase I study PROFILE and received crizotinib mg twice daily in day cycles, a dose which was established in the dose-escalation phase of the study.
In the present case, crizotinib was used as a fourth-line therapy and a therapeutic caae was achieved.
Here we present the case of a year-old patient who presented with multiple pulmonary nodules, a left pleural effusion and an ovarian tumor. Usage and distribution for commercial purposes requires written permission.
XALKORI case study | TIGCRU Insight
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. Nat Rev Clin Oncol. Additionally, the same study listed several adverse events which could be associated with the esophagus, such as heartburn and reflux esophagitis 8. Abstract Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase ALK gene rearrangement, is generally well tolerated. Written informed consent was obtained from the patient for publication of this case report.
Several studies have confirmed that alectinib is an effective alternative in patients for whom crizotinib has been discontinued because of serious AEs such as dysgeusia and esophageal ulceration [ 1314 ].
XALKORI case study
This article has been cited by other articles in PMC. In addition, post hoc analyses showed that general health status measured using the EuroQol-5D instrument was significantly better in crizotinib-treated xalkiri score 0.
A correction has been published: Furthermore, this clinical trial confirmed that the incidence of severe neutropenia was higher in the high-dose group than in the low-dose group. These patients had significantly longer overall survival from the xalkoti of progression median Active EGFR mutations were not identified.
Citing articles via Web of Science Thus, we conclude that the pathogenesis of neutropenia in the present case might be associated with the inhibitory action against the c-Met receptor rather than an immune-mediated reaction. A notable difference in the myelotoxicity between crizotinib and alectinib treatment was observed in the present patient.
However, there are currently few reports of detailed clinical experience and management of severe neutropenia in these patients.
With regard to the adverse effects, crizotinib was demonstrated to be tolerable 34. In this case, the patient exhibited an eminently prolonged response to pemetrexed, which preceded crizotinib treatment. However, information concerning clinical experience and management of severe neutropenia is currently limited.
Relapse was experienced following third-line chemotherapy with pemetrexed and anaplastic lymphoma kinase ALK -positive adenocarcinoma was diagnosed using a specimen from the resected ovarian tumor. Author information Article notes Copyright and License information Disclaimer. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: View large Download slide. Statement of Ethics Written informed consent was obtained from the patient for publication of this case report. CH, a selective ALK inhibitor capable of blocking the casr gatekeeper mutant.